ESMO Media Releases

ESMO is pleased to announce the ESMO Immuno-Oncology 2018 Congress, a dedicated platform in Europe to keep professionals up to date with the most recent and significant developments in this rapidly evolving field.

Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients – challenges which are best addressed through collaboration in international networks.

Misconceptions about the use of strong opioids showed to undermine optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy according to a cross-sectional survey conducted at the Sarawak General Hospital in Malaysia.

The European Society for Medical Oncology (ESMO) has selected Prof. Cornelis Melief to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer.

The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, is pleased to announce the third ESMO Asia 2018 Congress. 

Patients with HPV-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival

Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer

Two-year maintenance therapy with olaparib, a PARP inhibitor, olaparib, led to improvement in PFS